|Bid||4.4100 x 1100|
|Ask||4.4700 x 1000|
|Day's Range||4.3800 - 5.1000|
|52 Week Range||3.1260 - 369.0000|
|Beta (3Y Monthly)||-0.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shave of Viveve Medical Inc. sank 9.7% toward a record low in premarket trading Friday, after the provider of health products and women's health services filed for the sale of new common stock to the public. The number of Class A common shares or Class B preferred shares the company will sell, or at what price the shares will be sold, has not yet been determined, according to a filing with the Securities and Exchange Commission. The stock has plummeted 91% over the past three months through Thursday, while the S&P 500 has eased 2.1%.
I hate to keep harping on this theme, but recent personal experience has shown that the new month brings a new market. And boy am I thankful that this month happens to be October. For one, September petered ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Viveve Medical (NASDAQ: VIVE ) shares were ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
By Brian Marckx, CFA READ THE FULL VIVE RESEARCH REPORT NASDAQ:VIVE Viveve (NASDAQ:VIVE) reported financial results for their fiscal Q1’19 and provided a business update. Relative to the financials, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 11) Edap Tms SA (NASDAQ: EDAP ) Down In The Dumps (Biotech ...
Q4 Results: Warning Letter Headwinds Persist, Although Dissipating. Viveve (VIVE) reported Q4 financial results and provided a business update. While this is down 12% from the prior year, it is about 16% better than what we had anticipated (prior to the preannouncement) and, per management’s comments on the call, reflective of the continued hangover from FDA’s late-July warning letter (which, as a reminder, was not addressed to Viveve but did cause industry-wide disruptions).
Viveve Medical Inc is a women's sexual health company focused on the commercialization of a non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Warning! GuruFocus has detected 4 Warning Signs with VIVE.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
Earlier this week Viveve (VIVE) preannounced expected Q4 revenue of ~$4.4M (~16% ahead of our since-revised estimate), issued initial 2019 revenue guidance of $20.0M (~17% below our since-revised estimate) and outlined an already-underway operational restructuring plan aimed at slashing expenses and refocusing sales efforts at the physician (i.e. Q4 numbers (vs our estimates) are 57 (vs 55 E) unit sales, including 48 (vs 40 E) in the U.S. and 9 (vs 15) OUS and 4,600 (vs 5,047 E) consumable treatment tips. The ~$4.4M in expected Q4 revenue implies declines of 13% from Q4’17 and 8% from Q3’18.
It has been a busy few weeks for Viveve (VIVE). In addition to raising nearly $19M (net) via the sale of common shares, they recently announced compelling 12-month results from their n=36 SUI feasibility study and got the green light from FDA to forge ahead with VIVEVE II (their pivotal U.S. study in sexual function). Earlier this month Viveve announced 12-month results of its feasibility study evaluating their Viveve System technology for the treatment of women with mild-to-moderate stress urinary incontinence (SUI).
Viveve (VIVE) reported Q3 2018 financial results and provided a business update. While VIVE was not one of the seven, we are not overly surprised that this has caused what appears to be an overly cautious market reaction given FDA’s language in the letter that these devices (i.e.
If you’re interested in Viveve Medical Inc (NASDAQ:VIVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...